礼来公司在波士顿开设新的 7 亿美元基因医学创新中心
【中美创新时报2024 年9 月 8 日波士顿讯】（记者温友平编译）近日，世界上最大的制药公司礼来公司（Eli Lilly）在波士顿正式开设了新的研发设施，将约 700 名生物技术工人带入海港地区。masslive记者Irene Rotondo对此作了下述报道。
位于海港区 Fort Point 街区 Necco 街 15 号，耗资 7 亿美元的礼来海港创新中心 (LSC) 将雇用该公司 500 名专注于基因疗法的科学家和研究人员。
礼来研究实验室首席科学官兼总裁、礼来免疫学总裁丹尼尔·斯科沃隆斯基（Daniel Skovronsky ）在一份新闻稿中表示：“我们致力于成为这个发现和创新中心的支持邻居。”
他补充说，该大楼的开放“扩大了礼来在波士顿地区的长期影响力”，并将允许“与领先机构和新人才”进一步合作。
LSC 高级总监兼首席运营官迈克尔·哈里森周一告诉《波士顿商业杂志》，这家制药巨头之前在东海岸的枢纽于 2015 年在剑桥开业，当时只有 10 名员工，如今已发展到 200 多名。
他补充说，礼来不打算保留剑桥的空间。
“事实上，我们已经从那个空间发展出来了，我们将海港视为继续发展和创新的机会，”礼来研发传播副总监艾莉森·豪威尔告诉媒体。
新的占地 346,000 平方英尺、12 层高的场地将容纳实验室和办公空间，用于开发针对糖尿病、肥胖症、心血管疾病、神经退行性疾病和慢性疼痛等疾病的药物。
礼来网关实验室（Lilly Gateway Labs ）也将并入该空间，为来自 12 至 15 家其他成员公司的另外 200 名员工提供培训。
该孵化计划允许初创生物技术公司从这家制药巨头那里获得资源、指导和资金。 Howell 告诉《商业日报》，虽然“没有任何附加条件”，而且这些公司不需要与 Lilly 合作，但他们确实有机会这样做。
据该媒体报道，创新中心的便利设施包括一辆由 Airstream 改装的“内部餐车”、一间游戏室和一个屋顶平台。
题图：礼来海港创新中心 (LSC)。图片由礼来公司提供
附原英文报道：
Eli Lilly opens new $700M Boston genetic medicine innovation hub
The world’s largest pharmaceutical company, Eli Lilly and Company, is bringing about 700 biotech workers into the Seaport area after it officially opened its new research and development facility in Boston on Tuesday.
Located at 15 Necco St. in the Fort Point neighborhood along the Seaport district, the $700 million Lilly Seaport Innovation Center, or LSC, will employ 500 of the company’s scientists and researchers focused on genetic therapies.
“We are committed to being supportive neighbors in this hub of discovery and innovation,” Daniel Skovronsky, chief scientific officer and president, Lilly Research Laboratories, president, Lilly Immunology, said in a release.
He added the building’s opening “expands upon Lilly’s long-standing presence in the Boston area” and will allow for further collaboration “with leading institutions and new talent.”
The pharma giant’s previous hub on the East Coast had opened in Cambridge in 2015 with 10 employees and has since grown to more than 200, LSC Senior Director and Chief Operations Officer Michael Harrison told the Boston Business Journal on Monday.
Lilly does not plan on keeping the Cambridge space, he added.
“The fact of the matter is that we grew out of that space and we saw Seaport as an opportunity to continue to grow and innovate,” Allison Howell, associate director of R&D communications at Lilly, told the outlet.
The new 346,000-square-foot, 12-story site will house laboratories and office space for medicine development to target illnesses such as diabetes, obesity, cardiovascular diseases, neurodegeneration and chronic pain.
Lilly Gateway Labs will also be integrated into the space to bring an additional 200 employees from 12 to 15 other member companies.
Read more: Brigham and Women’s nurses reach ‘significant settlement’ to deter strike
This incubation program allows startup biotechs to receive resources, guidance and funding from the pharma giant. Though there’s “no strings attached” and the companies do not need to partner with Lilly, they do have the opportunity to do so, Howell told the Business Journal.
An “internal food truck” out of an Airstream, a gaming room and a rooftop deck top off amenities at the innovation hub, the outlet reported.
